Close Menu

NEW YORK (GenomeWeb) – Illumina said today that an expanded version of its VeriSeq NIPT software to analyze fetal aneuploidies has met the requirements of the EU's in vitro diagnostic directive and it will apply the CE mark to the software.

The VeriSeq NIPT test is a noninvasive prenatal test that analyzes fetal aneuploidy for chromosomes 21, 18, 13, as well as the sex chromosomes.

The updated software includes a new method for processing samples and an increase in the number of samples it can batch from 16 to 48.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.